Get access

Tribbles 2 (Trib2) is a novel regulator of toll-like receptor 5 signaling

Authors

  • Shu-Chen Wei MD, PhD,

    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    2. Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taiwan
    Search for more papers by this author
  • Ian M. Rosenberg PhD,

    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Zhifang Cao PhD,

    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Alan S. Huett PhD,

    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Ramnik J. Xavier MD, PhD,

    Corresponding author
    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    2. Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, MA 02114
    Search for more papers by this author
  • Daniel K. Podolsky MD

    1. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, Massachusetts
    2. UT Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author

  • Supported by NIH funds DK060049 and DK043351 (to R.J.X.), the Ministry of Education of Taiwan (Taiwan Study Abroad Scholarship), the National Science Council of Taiwan (NSC-095-SAF-I-564-604-TMS, NSC-98-2314-B-002-094-MY2), the National Taiwan University Hospital (NTUH-97-N1038, NTUH-98-N1197), and by the Liver Disease Prevention & Treatment Research Foundation.

Abstract

Background:

Toll-like receptors (TLRs) are expressed by a variety of cells, including intestinal epithelia. However, the full spectrum of regulators modulating innate responses via TLRs has not been delineated. Tribbles (Trib) have been identified as a highly conserved family of kinase-like proteins. We sought to clarify the role of Trib2 in the TLR signaling pathway.

Methods:

Trib2 mRNA and protein levels were analyzed by quantitative polymerase chain reaction (PCR) and western blot, respectively. Immunohistochemical staining was used to determine the expression of Trib2 in human tissue. Involvement of Trib2 in nuclear factor kappa B (NF-κB) pathways was assessed in epithelial cells by NF-κB reporter assay. Proteins that interacted with Trib2 were identified by mass spectrometry and confirmed by immunoprecipitation. The domain essential for Trib2 function was mapped using truncated constructs.

Results:

Trib2 expression is decreased in active inflamed tissue from patients with inflammatory bowel disease (IBD). Trib2 is expressed in human and mouse colonic epithelium as well as immune cells, and its expression in epithelium is inducible in a ligand-dependent manner by TLR5 ligand stimulation. Trib2 inhibits TLR5-mediated activation of NF-κB downstream of TRAF6. Trib2 selectively modulates mitogen-activated protein kinase (MAPK) pathways p38 and Jun N-terminal kinase (JNK) but not p44/p42 (ERK1/2). NF-κB2 (p100) was identified as a Trib2 binding partner in regulating the TLR5 signaling pathway that leads to inhibition of NF-κB activity. Residues 158–177 in the Trib2 kinase-like domain are required for Trib2 function.

Conclusions:

These observations indicate that Trib2 is a novel regulator in the TLR5 signaling pathway and altered expression of Trib2 may play a role in IBD. (Inflamm Bowel Dis 2012;)

Get access to the full text of this article

Ancillary